Business Details
Your Partner in Biopharmaceutical Innovation
Collegium Pharmaceutical is a dedicated biopharmaceutical company focused on improving the lives of individuals with serious medical conditions. Our team is driven by the belief that those living with such conditions deserve to fully engage in daily life and spend quality time with loved ones. We are committed to developing a diversified portfolio of differentiated medications that address severe and persistent pain, ADHD, and other critical healthcare needs. Our values of integrity, accountability, and community stewardship guide every aspect of our operations, from research and development to corporate social responsibility.With a leadership team boasting decades of industry experience, we combine scientific innovation with a patient-centric approach to deliver meaningful medicines. Our partnerships with healthcare professionals and formulary decision makers ensure our treatments reach those who need them most. Through responsible pain management and neuropsychiatric therapies, we strive to create a lasting impact on patients, providers, and communities alike.
Services
Jornay PM
Belbuca
Xtampza ER
Nucynta
Symproic
Highlights and features
- We lead with science to support people with serious medical conditions.
- We focus on improving health and well-being of communities through responsible citizenship.
- We have a portfolio of differentiated medications for pain and ADHD.
- Our team combines decades of industry experience with patient-centric values.
- We uphold integrity and accountability in all aspects of our biopharmaceutical business.
Services
Jornay PM
Jornay PM is a prescription medication for ADHD treatment, designed to provide extended symptom control into the evening. It uses proprietary technology to delay and prolong methylphenidate release. This once-daily treatment helps patients maintain focus and manage impulsivity throughout the day and night.
Belbuca
Belbuca is a buccal film for chronic pain management, delivering buprenorphine through the inner cheek. It offers around-the-clock relief for severe pain requiring continuous treatment. This transmucosal formulation provides consistent medication levels while minimizing misuse potential compared to traditional opioids.
Xtampza ER
Xtampza ER is an extended-release oxycodone formulation for managing severe pain requiring continuous treatment. Its unique DETERx platform allows consistent medication release regardless of food intake. This opioid therapy option provides 12-hour pain relief with reduced dose frequency compared to immediate-release formulations.
Nucynta
Nucynta offers both immediate-release and extended-release formulations for moderate to severe acute pain management. As an opioid agonist with dual mechanisms, it provides flexible dosing options for varying pain severity. The medication works by binding to central nervous system receptors to alter pain perception.
Symproic
Symproic is a once-daily pill for managing opioid-induced constipation in adults with chronic non-cancer pain. As a peripherally acting mu-opioid receptor antagonist, it targets gastrointestinal tract receptors without affecting central pain relief. This treatment helps maintain regular bowel function during long-term opioid therapy.
People
Vikram Karnani
President & Chief Executive Officer
Vikram Karnani leads Collegium Pharmaceutical with over 20 years of biopharma leadership, including executive roles at Amgen and Horizon Therapeutics. He holds electrical engineering degrees from University of Mumbai and Case Western Reserve University, plus an MBA from Kellogg School of Management.
Colleen Tupper
Chief Financial Officer
Colleen Tupper brings extensive finance leadership from Takeda and Shire Pharmaceuticals, where she managed global financial operations and strategic initiatives. She earned a B.S. in Accounting from Franklin Pierce University and has over 25 years of pharmaceutical industry experience.
Thomas Smith
Chief Medical Officer
Dr. Thomas Smith has 25+ years of medical leadership experience, including roles at BioDelivery Sciences and Mallinckrodt Pharmaceuticals. A physician with dual degrees from Indiana University and Purdue University, he specializes in clinical development and medical affairs strategy.
Scott Sudduth
Head of Technical Operations
Scott Sudduth oversees technical operations with prior leadership roles at Moderna and Sanofi Genzyme. He holds a B.S. in Biology from Clarkson University and has managed complex supply chains for biopharmaceutical products across multiple therapeutic areas.
Gino Santini
Chairman of the Board
Gino Santini serves as Board Chairman with 27 years of executive experience at Eli Lilly and leadership roles in biotech ventures. He holds engineering and business degrees from University of Bologna and University of Rochester, with extensive board governance expertise.
Questions
What therapeutic areas does Collegium Pharmaceutical focus on?
We specialize in pain management and neuropsychiatry, developing treatments for chronic pain and ADHD while maintaining responsible medication stewardship.
How can healthcare professionals access medical information?
Our Medical Affairs portal provides detailed prescribing information, medication guides, and safety documentation for licensed healthcare professionals.
What makes Collegium's medications different?
We develop differentiated formulations using advanced delivery technologies that improve medication efficacy, safety, and patient convenience.
How does Collegium support responsible medication use?
Our programs emphasize proper prescribing practices, patient education, and monitoring to ensure safe use of controlled substances.
Where are Collegium products available?
Our medications are distributed nationwide through U.S. pharmaceutical channels to qualified healthcare providers and patients.
How can investors access company information?
Investor relations materials including financial reports, SEC filings, and corporate governance documents are available in our Investors section.
